DK0633929T3 - Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener - Google Patents

Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener

Info

Publication number
DK0633929T3
DK0633929T3 DK93911581T DK93911581T DK0633929T3 DK 0633929 T3 DK0633929 T3 DK 0633929T3 DK 93911581 T DK93911581 T DK 93911581T DK 93911581 T DK93911581 T DK 93911581T DK 0633929 T3 DK0633929 T3 DK 0633929T3
Authority
DK
Denmark
Prior art keywords
dendritic cell
antigens
cell precursors
antigen
producing
Prior art date
Application number
DK93911581T
Other languages
English (en)
Inventor
Ralph M Steinman
Kayo Inaba
Gerold Schuler
Original Assignee
Univ Rockefeller
Merix Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Merix Bioscience Inc filed Critical Univ Rockefeller
Application granted granted Critical
Publication of DK0633929T3 publication Critical patent/DK0633929T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4528—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK93911581T 1992-04-01 1993-04-01 Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener DK0633929T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86161292A 1992-04-01 1992-04-01
US98135792A 1992-11-25 1992-11-25
US4067793A 1993-03-31 1993-03-31

Publications (1)

Publication Number Publication Date
DK0633929T3 true DK0633929T3 (da) 2004-06-28

Family

ID=27365767

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93911581T DK0633929T3 (da) 1992-04-01 1993-04-01 Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener

Country Status (9)

Country Link
US (5) US5994126A (da)
EP (1) EP0633929B1 (da)
JP (1) JP3649335B2 (da)
AT (1) ATE260971T1 (da)
CA (1) CA2133409C (da)
DE (1) DE69333433T2 (da)
DK (1) DK0633929T3 (da)
ES (1) ES2215991T3 (da)
PT (1) PT633929E (da)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3649335B2 (ja) * 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
US20020085993A1 (en) * 1992-11-25 2002-07-04 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US20010012632A1 (en) * 1995-03-31 2001-08-09 Muriel Moser Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US7150992B1 (en) * 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP0808897A1 (en) * 1996-05-21 1997-11-26 I.D.M. Immuno-Designed Molecules New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
JP2002514047A (ja) * 1996-07-10 2002-05-14 イミュネックス・コーポレーション 樹状細胞を活性化する方法
US6458585B1 (en) 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US20040110283A1 (en) * 1997-02-27 2004-06-10 University Of Pittsburgh Of The Commonwealth System Of Higher Education Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
US20050169898A1 (en) * 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
CA2286873C (en) 1997-04-15 2010-07-13 Dana-Farber Cancer Institute, Inc. Dendritic cell hybrids
AU7499498A (en) * 1997-05-21 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells
EP0922758B1 (en) 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US20020034819A1 (en) * 1998-02-23 2002-03-21 Alan K. Smith Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
WO1999050392A1 (en) 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
EP1138692A1 (en) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US20020051783A1 (en) * 1998-06-05 2002-05-02 Savage Philip Michael Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7264965B2 (en) * 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7521197B2 (en) * 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
US20020090381A1 (en) * 1999-04-09 2002-07-11 H. Kim Bottomly System for controlling immune system response to antigen
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
CA2373300C (en) 1999-04-14 2012-02-21 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
SG143935A1 (en) 1999-05-06 2008-07-29 Univ Wake Forest Compositions and methods for identifying antigens which elicit an immune response
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7713739B1 (en) * 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
RU2263118C2 (ru) 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
US7651998B1 (en) 1999-08-31 2010-01-26 The University Of North Carolina At Chapel Hill Antibody dependent enhancement of Venezuelan Equine Encephalitis vector infection
EP1224264B1 (en) 1999-10-15 2010-01-27 Baylor Research Institute Use of allogeneic cell lines to load antigen-presenting cells to elicit immune responses
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2001051617A1 (en) * 2000-01-11 2001-07-19 Maxygen, Inc. Monocyte-derived dendritic cell subsets
WO2001051500A1 (en) * 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6423539B2 (en) 2000-02-24 2002-07-23 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001062092A1 (en) * 2000-02-25 2001-08-30 Thomas Jefferson University Formulations and methods for using the same to elicit an immune response
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7361329B2 (en) * 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells
US7517526B2 (en) * 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
NZ525829A (en) * 2000-10-13 2005-04-29 Norwood Immunology Ltd Improvement of graft acceptance by T cell ablation, areactivating the thymus and adminstrating hematopoietic or epithelial stem cells or progenitor cells
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US20020094545A1 (en) * 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
US20030027334A1 (en) * 2000-12-13 2003-02-06 Fitzpatrick David R. Method for generating immortal dendritic cell lines
AU3069302A (en) * 2000-12-13 2002-06-24 Immunex Corp Method for generating immortal dendritic cell lines
PT1366067E (pt) 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
WO2002074921A2 (en) * 2001-03-19 2002-09-26 Cellular Genomics Inc. Methods for isolating proteins expressed by dendritic cells
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
AU2002249531A1 (en) * 2001-04-02 2002-10-28 Alimentary Health Limited Immunotherapy based on dendritic cells
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
CA2448599A1 (en) * 2001-04-27 2002-11-07 Invitrogen Corporation Maturation of antigen-presenting cells using activated t cells
KR20020083634A (ko) * 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030149646A1 (en) * 2002-02-01 2003-08-07 Ubs Painewebber Inc. Method and system for providing an aggregated stock options report
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US7060494B2 (en) * 2002-04-09 2006-06-13 Reliance Life Sciences Pvt. Ltd. Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the preparation thereof
US7763251B2 (en) * 2002-04-12 2010-07-27 Medical College Of Georgia Research Institute, Inc. Kits to assess the risk of tumor progression
MXPA04011071A (es) 2002-05-08 2005-07-14 Northwest Biotherapeutics Inc Analisis de calidad para celulas que presentan antigenos.
US7332158B2 (en) * 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
CA2388441A1 (en) * 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
AU2003267088A1 (en) * 2002-09-11 2004-04-30 Medical College Of Georgia Research Institute, Inc. Chemokine receptor antagonists as therapeutic agents
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
CN1738914A (zh) 2002-11-21 2006-02-22 震源技术公司 使用编码双链启动子一条链的引物的方法
CN1738619B (zh) 2002-12-06 2012-04-18 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤的制药用途
ES2346205T3 (es) 2002-12-17 2010-10-13 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticurpo 14.18 de raton que se enlaza con gd2 y su fusion con la il-2.
WO2004063963A2 (en) * 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
EP1583423A4 (en) * 2003-01-16 2006-05-10 Becton Dickinson Co INTRADERMAL DISTRIBUTION OF CELLS USING THIN MICROCANULA
US20040197903A1 (en) * 2003-01-31 2004-10-07 Northwest Biotherapeutics, Inc. Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15
BRPI0407002A (pt) * 2003-02-10 2006-01-10 Northwest Biotherapeutics Inc Células cultivadas que apresentam antìgeno cd14+
US20060134067A1 (en) * 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
US7745157B2 (en) * 2003-02-21 2010-06-29 University Of Maryland, Baltimore Human lymphocyte medium adjuvant
PL209998B1 (pl) * 2003-02-27 2011-11-30 Northwest Biotherapeutics Inc Sposób in vitro lub ex vivo różnicowania monocytarnych prekursorów komórek dendrytycznych w niedojrzale komórki dendrytyczne
EP1608728A2 (en) * 2003-03-31 2005-12-28 University Of South Florida Research Foundation, Inc. Materials and methods for regulating process formation in cell culture
US20040203142A1 (en) * 2003-04-14 2004-10-14 Reliance Life Sciences Pvt. Ltd. Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes
CA2533121A1 (en) * 2003-07-22 2005-01-27 Kirin Beer Kabushiki Kaisha Method of preparing langerhans cell from cd14-positive cell being human peripheral-blood mononuclear cell with use of notch ligand delta-1, gm-csf and tgf-.beta.
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
US20070087986A1 (en) * 2004-01-26 2007-04-19 Brett Premack Compositions and methods for enhancing immunity by chemoattractant adjuvants
EP1711206A2 (en) * 2004-01-26 2006-10-18 ChemoCentryx Inc Compositions and methods of use of w-peptides
US20050214268A1 (en) * 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
EP1757680B1 (en) * 2004-05-11 2009-09-16 Shukokai Incorporated Methods for cultivating antigen presenting cells
CA2566473A1 (en) * 2004-05-17 2005-12-08 Board Of Trustees Of The University Of Illinois Uses of bispecific antibody (biab) coated dendritic cells pulsed with antigens
EP1773403B1 (en) * 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US20060057121A1 (en) * 2004-09-10 2006-03-16 Demao Yang Compositions and treatments using ex vivo activated cells for myelosuppressed patients
JP5269412B2 (ja) 2004-10-07 2013-08-21 アルゴス セラピューティクス，インコーポレイティド 成熟樹状細胞組成物およびその培養方法
JP2008520684A (ja) * 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
US20090028876A1 (en) * 2005-01-24 2009-01-29 University Of Rochester Methods of modifying cd11c+ dendritic cell development to form osteoclasts functional in the bone environment
US8486420B2 (en) * 2005-02-15 2013-07-16 The University Of North Carolina At Chapel Hill Live virus vaccines
JP2008539751A (ja) * 2005-05-10 2008-11-20 アヴァリス・アーベー 新規組成物およびその使用
EP1888105A2 (en) * 2005-05-12 2008-02-20 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
CN101217971B (zh) * 2005-07-05 2011-11-09 比奥滕普特公司 肿瘤的治疗
EP1957634A4 (en) 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc COMPOSITIONS AND METHODS OF INDUCING THE ACTIVATION OF UNREFERENCE MONOCYTIC DENDRITE CELLS
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
JP2009542714A (ja) 2006-06-30 2009-12-03 ベイラー リサーチ インスティテュート ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
CA2700573C (en) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
GB0622399D0 (en) * 2006-11-10 2006-12-20 Avaris Ab Novel compositions and uses thereof
US20080286315A1 (en) * 2007-01-31 2008-11-20 Penta Biotech, Inc. Methionine Enkephalin as an Adjuvant for Vaccine Immunizations
DE102007006736B4 (de) 2007-02-07 2012-01-12 Dagmar Briechle In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz
KR100887560B1 (ko) * 2007-04-24 2009-03-09 크레아젠 주식회사 준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물
AU2008280436A1 (en) * 2007-07-24 2009-01-29 Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre Compositions and methods for generating an immune response in a subject
US8513208B2 (en) 2008-02-28 2013-08-20 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
DK2328923T3 (da) * 2008-09-02 2016-03-21 Cedars Sinai Medical Center Cd133-epitoper
ES2618573T3 (es) * 2009-05-07 2017-06-21 ImmunoCellular Therapeutics,Ltd Epítopos de CD133
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
WO2012115276A1 (en) * 2011-02-23 2012-08-30 Kyoto University Method for producing dendritic cells from pluripotent stem cells
SG11201404570WA (en) * 2012-02-10 2014-11-27 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
AU2014348184B2 (en) * 2013-11-18 2020-08-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
US10350279B2 (en) 2014-06-23 2019-07-16 Jw Creagene Inc. Method for preparing dendritic cells with increased specific gene expression, and composition for treating or preventing autoimmune diseases, containing dendritic cells prepared using same
US10849985B2 (en) 2015-05-20 2020-12-01 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
US20170216354A1 (en) * 2015-06-12 2017-08-03 Batu Biologics, Inc. Clinically useful non-antigen pulsed dendritic cells
CA2990640A1 (en) 2015-06-30 2017-01-05 Northwest Biotherapeutics, Inc. Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
KR20180044430A (ko) 2015-09-15 2018-05-02 노쓰웨스트 바이오써라퓨틱스, 인크. 진행성 암을 가진 대상체를 위한 활성화된 수지상 세포 조성물 및 면역요법적 치료와 관련된 방법
AU2016355191B2 (en) 2015-11-18 2023-06-29 Orbis Health Solutions Llc T7 alpha viral vector system
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
EP3706784A4 (en) 2017-11-08 2021-12-01 BioNTech US Inc. COMPOSITIONS AND METHODS OF MANUFACTURING T-CELLS
CN112243382A (zh) 2018-01-18 2021-01-19 南佛罗里达大学 死抗原刺激的未成熟异源性树突细胞作为疾病治疗剂
WO2019246111A1 (en) 2018-06-19 2019-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
US5364783A (en) * 1990-05-14 1994-11-15 Massachusetts Institute Of Technology Retrovirus promoter-trap vectors
IL103928A0 (en) * 1991-12-11 1993-04-04 American Home Prod Expression of specific immunogens using viral antigens
EP0563485A1 (en) * 1992-03-30 1993-10-06 Schering-Plough In vitro generation of human dendritic cells and uses thereof
JP3649335B2 (ja) * 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US20020085993A1 (en) 1992-11-25 2002-07-04 Ralph M. Steinman Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
WO1995015340A1 (en) * 1993-12-03 1995-06-08 The Board Of Trustees Of Leland Stanford Junior University Monoclonal antibodies to antigens expressed by human dendritic cells
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
JPH10504284A (ja) * 1994-06-14 1998-04-28 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティー 抗原パルス化樹状細胞によるｉｎ ｖｉｖｏ Ｔ細胞活性化法
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP0922758B1 (en) 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells

Also Published As

Publication number Publication date
CA2133409A1 (en) 1993-10-14
EP0633929B1 (en) 2004-03-03
DE69333433D1 (de) 2004-04-08
US5994126A (en) 1999-11-30
US20090029469A1 (en) 2009-01-29
US7923247B2 (en) 2011-04-12
JP3649335B2 (ja) 2005-05-18
US20030134419A1 (en) 2003-07-17
JP2002507881A (ja) 2002-03-12
DE69333433T2 (de) 2004-12-02
US5851756A (en) 1998-12-22
ES2215991T3 (es) 2004-10-16
ATE260971T1 (de) 2004-03-15
CA2133409C (en) 2011-05-24
PT633929E (pt) 2004-07-30
EP0633929A1 (en) 1995-01-18
US6475483B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
HUP0500477A2 (hu) Eljárások és készítmények embrionális és felnőttkori őssejtek támogatására stromasejtek alkalmazásával
ATE432085T1 (de) Stimulationsfaktor für dendriten
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
DK1220934T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner med anvendelse af apoptoseinhibitorer
DE69521794D1 (de) Zellen mit mehreren geänderten epitopen auf einem oberflächeantigen zur verwendung in transplantation
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
DK0633930T3 (da) In vitro dannelse af humane dendritiske celler
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
DK0789588T3 (da) Metode til fremstilling af et medikament til behandling af sekundær immundefekt
DE69534595D1 (de) Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
Sun et al. Unique roles of Schistosoma japonicum protein Sj16 to induce IFN‐γ and IL‐10 producing CD4+ CD25+ regulatory T cells in vitro and in vivo
DK0587873T3 (da) Fremgangsmåde til opnåelse af celler, der er inficeret med en virus, der er forbundet med dissemineret sklerose
DK1093465T3 (da) Fremgangsmåde til frembringelse eller forögelse af en T-cellerespons mod en målcelle ved brug af kompleks omfattende et HLA klasse I molekyle og et tilkoblingsorgan
WO2003020904A3 (en) Methods of generating human cd4+ th1 cells
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
BOROS et al. Endogenous IL‐10 regulates IFN‐γ and IL‐5 cytokine production and the granulomatous response in Schistosomiasis mansoni‐infected mice
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
DE69333547D1 (de) Therapeutische anwendungen von chimänischer organogenese
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
NO20032097L (no) Gj¶ravledet vaksine mot IPNV
ATE322540T1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
ATE248914T1 (de) Allogenes vakzin und synthesemethode für selbiges
Helbig et al. Taking CD4 T Cells Up a Notch